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Genotropin allowed further evaluation of the IGF-1 SDS 
analysis paradigm.
Enrolled subjects were randomized to receive treat-
ment with either once weekly Somatrogon (0.66 mg/kg; 
N=109) or once daily Genotropin (0.034 mg/kg; N=115). 
IGF1 was sampled ~ five times during 52 weeks of 
treatment with Somatrogon, providing a total of 557 
samples obtained after the first dose of Somatrogon. 
IGF-1 SDS values were calculated using Bidlingmaier’s 
equations [2].
Analysis of IGF-I SDS data from the Phase 3 study showed 
that the previously-developed model, with adjustments to 
two parameters (baseline IGF-1, EC
50
) and adapted to it 
IGF-1 values in the absence of Somatrogon concentration 
data, it the IGF-1 data for Somatrogon with minimal bias. 
This allowed prediction of IGF-1 SDS values at timepoints 
throughout the dosing interval as well as calculation of 
the mean value during a dosing interval. Of the samples 
obtained between 48–72 hours post-dose (representing 
peak IGF-1 SDS), approximately 17% had an IGF1 SDS > 
+2. At 96 hours (corresponding to mean IFG-1 SDS), fewer 
than 2% of modeled values were > +2. Mean IGF-1 SDS over 
the dosing interval was between -1 and +1 for all subjects.
These indings indicate that IGF-1 SDS values need to be 
interpreted in the context of when the sample was obtained 
relative to the last dose of Somatrogon. Our results indi-
cate that samples obtained 96 hours post-dose best repre-
sent mean IGF-1 levels and that values obtained between 
48–72 hours post-dose represent values closer to peak 
IGF-1 concentrations. In our Phase 3 study, of the 557 
samples collected from 114 patients during the 12-month 
Somatrogon treatment period, fewer than 2% of the cor-
responding values at 96 hours postdose (estimated from a 
pharmacokinetic/pharmacodynamic model) had IGF-1 SDS 
levels > +2.
1. Fisher DM, et  al. Horm Res Paediatr 2017;87:324. 
2.  Bidlingmaier M, et  al. J Clin Endocrinol Metab 
2014;99:1712
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Background:
In vivo animal models for testing the pharmacoki-
netics and bioactivity of PTH and its analogues require 
parathyroidectomy by surgery (1, 2). As the parathyroid 
glands of rodents are very small the surgery often includes 
thyroidectomy, making this animal model time-limited, 
single use, complex, and expensive. We have developed a 
non-surgical rodent model of hypoparathyroidism using 
the Type II calcimimetic compound, Cinacalcet-HCl, to sup-
press PTH and thereby serum calcium levels.
Methods:
Normal male Wistar rats were gavaged with 30  mg/kg 
Cinacalcet-HCl (or vehicle only). To test the effect of PTH 
1–34, animals were dosed immediately after Cinacalcet-
HCl gavage with either a single subcutaneous injection 
of PTH at 20  nmol/kg or given as same dose repeated 
every hour for 6 hrs or vehicle only. Serum samples were 
analysed for ionised calcium (iCa) using an EasyLyte, fully 
automated electrolyte analyser (Medica Corporation) and 
phosphate using a Phosphorus Detection Assay Kit (Pars 
Azmun, IRAN) and an Hitachi 917 Clinical Chemistry 
Analyser.
Results:
Rats gavaged with 30  mg/kg Cinacalcet-HCl produced a 
signiicant reduction in iCa levels between 2-24hrs re-
turning to baseline at 48-72hrs post dose with the nadir 
at 8 hours (ANOVA P < 0.0001). This equated to a 25% re-
duction in iCa at 8 hrs: mean±SD, iCa 1.19 ± 0.09 mmol/L 
at predose and 0.891  ± 0.04  mmol/L at 8 hours (t-test 
P < 0.0001). For phosphate there was an initial lowering 
within the irst 2 hrs in all test groups but then a rise 
such that phosphate was at higher levels than control 
from 8–24 hrs (ANOVA, ns), returning to baseline at 48 
hrs. PTH at 20 nmol/kg given as a single sc dose abrogated 
the Cinacalcet-HCl induced fall in iCa for up to 2 hrs 
(AUC±SD (mmol/L).hr, 0.076 ±0.047 versus 0.168±0.0874, 
t-test P=0.0289).
Conclusions:
We have shown that the administration of Cinacalcet-HCl 
provides a robust and reproducible lowering of calcium 
which is line with current published data (3). These studies 
demonstrate that the use of Cinacalcet-HCl in normal rats 
produces a hypocalcemic state that can be abrogated by the 
addition of PTH. This non-surgical animal model of hypo-
parathyroidism will be of value in testing the pharmacody-
namics of PTH analogues.
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